Cadus announces initial determination by USPTO rejecting all claims of patent at issue in Sibia litigation.(Brief Article)(Statistical Data Included)

BIOTECH Patent News, March, 2000

Cadus Pharmaceutical Corporation (Tarrytown, NY; 914-467-6200) announced that the United States Patent and Trademark Office has issued an office action, in connection with the pending re-examination of United States Patent 5,401,629 (the "'629 Patent") issued to SIBIA Neurosciences, Inc. (La Jolla, CA; 619-452-5892), rejecting all claims of the '629 Patent. The '629 Patent is the subject of SIBIA's patent infringement litigation against Cadus.

SIBIA brought suit against Cadus in July 1996 alleging infringement of the '629 Patent. In December 1998, a jury issued a verdict in favor of SIBIA and awarded SIBIA $18 million in damages. The judgment against Cadus based on the jury verdict is currently on appeal before the United States Court of Appeals for the...

Read the rest of this article with a Free Trial at HighBeam Research.

Premium Content Partnership | HighBeam Research provides an in-depth online archive library of reference works.